Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Japan Tissue Engineering Co., Ltd. ( (JP:7774) ) has provided an announcement.
Japan Tissue Engineering Co., Ltd. has released its financial report for the fiscal year ending March 2025, highlighting its business performance and topics for the year. The report includes an earnings forecast for the fiscal year ending March 2026, indicating the company’s strategic focus on advancing regenerative medical products and maintaining its position in the industry.
More about Japan Tissue Engineering Co., Ltd.
Japan Tissue Engineering Co., Ltd. operates in the regenerative medicine industry, focusing on the development and manufacturing of autologous cultured tissues. The company offers products such as JACE, JACEMIN, JACC, NEPIC, OCURAL, and LabCyte, which are used for various medical and research purposes.
Average Trading Volume: 300,762
Technical Sentiment Signal: Buy
Current Market Cap: Yen23.35B
See more insights into 7774 stock on TipRanks’ Stock Analysis page.